ClinicalTrials.gov
ClinicalTrials.gov Menu

Use of Diagnostic Measures in Chronic Obstructive Pulmonary Disease (COPD) in Routine Practice and Their Impact on Treatment Decisions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03465332
Recruitment Status : Completed
First Posted : March 14, 2018
Last Update Posted : January 15, 2019
Sponsor:
Collaborator:
Institut Dr. Schauerte (IDS)
Information provided by (Responsible Party):
GlaxoSmithKline

Brief Summary:
This study will evaluate the diagnostic measures (including blood eosinophil counts) commonly used by lung specialist's in routine clinical care of subjects with COPD in Germany and how these diagnostic tests influence the physician's treatment decisions. The study will be conducted in three parts. In the first part, lung specialist's, who will not participate in the survey, will develop doctor's questionnaire. The second part is an interventional cross-sectional study, wherein approximately 30 lung specialists will be enrolled and data on their perspective on diagnosis and treatment of COPD subjects will be collected via the revised doctor's questionnaire. The third part is a retrospective non-interventional study where each doctor will collect retrospective data from selected subjects with COPD from the time of informed consent up to 12 months before. The retrospective data will be collected from subject files of approximately 250 subjects with COPD.

Condition or disease Intervention/treatment
Pulmonary Disease, Chronic Obstructive Other: Doctor's questionnaire Other: Subject file

Study Type : Observational
Actual Enrollment : 251 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Use of Diagnostic Measures (Including Blood Eosinophil Counts) and Their Impact on Lung Specialists' Treatment Decisions in Patients With COPD in Germany
Actual Study Start Date : April 19, 2018
Actual Primary Completion Date : August 30, 2018
Actual Study Completion Date : August 30, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: COPD

Group/Cohort Intervention/treatment
Lung specialist
Approximately 30 lung specialists in Germany with a sufficient number of COPD subjects under supervision will be enrolled in the study to document physician's attitudes on COPD diagnosis and therapy, and to document data on about 250 subjects with COPD.
Other: Doctor's questionnaire
The survey of physicians will be performed using doctor's questionnaire, which will be developed by lung specialists who are not participating in the survey.

Subjects with COPD
Data from approximately 250 subjects with COPD under supervision of lung specialists enrolled in the study will be analyzed.
Other: Subject file
All subject-based data will be obtained by retrospective evaluation of subject files available at the treating lung specialist.




Primary Outcome Measures :
  1. Number of physicians with usage of diagnostic tests in routine clinical practice [ Time Frame: Up to 12 months ]
    The data on diagnostic test including blood eosinophil count commonly used by lung specialists in routine clinical practice will be obtained from doctor's questionnaire.

  2. Number of physician reported rationale for choice of diagnostic test [ Time Frame: Up to 12 months ]
    The reasons for choice of diagnostic test will be determined from doctor's questionnaires and from medical chart review.


Secondary Outcome Measures :
  1. Number of physician reported reasons for blood eosinophil test selection [ Time Frame: Up to 12 months ]
    The reasons blood eosinophil test selection will be analyzed using data from doctor's questionnaires.

  2. Number of physician reported reasons for drug selection [ Time Frame: Up to 12 months ]
    The selection of drugs by lung specialists for subjects with COPD will be analyzed using information obtained from medical chart review.

  3. Number of subjects with use of other diagnostic measures [ Time Frame: Up to 12 months ]
    Number of subjects with use of other diagnostic measures such as spirometry, X-ray, thoracic computer tomography and specific blood tests will be analyzed using data from subject files.

  4. Number of subjects with use of patient reported outcome (PRO) assessment [ Time Frame: Up to 12 months ]
    Number of subjects with use of questionnaires like COPD assessment test (CAT) and dyspnea assessment will be analyzed using data from subject files.

  5. Number of subjects with a history of respiratory medication [ Time Frame: Up to 12 months ]
    Number of subjects with a history of respiratory medication will be analyzed using data from subject files.

  6. Number of subjects receiving current medication [ Time Frame: Up to 12 months ]
    Number of subjects receiving current medication will be analyzed using data from subject files.

  7. Number of subjects receiving COPD maintenance treatment [ Time Frame: Up to 12 months ]
    Number of subjects receiving COPD maintenance treatment will be analyzed using data from subject files.

  8. Number of subjects receiving immunosuppressive treatment [ Time Frame: Up to 12 months ]
    Number of subjects receiving immunosuppressive treatment will be analyzed using data from subject files.

  9. Number of subjects receiving allergic treatment [ Time Frame: Up to 12 months ]
    Number of subjects receiving allergic treatment will be analyzed using data from subject files.

  10. Number of subjects receiving oral corticosteroids (OCS) for exacerbations [ Time Frame: Up to 12 months ]
    Number of subjects with maintenance and rescue use of OCS for exacerbations will be analyzed using data from subject files.

  11. Number of subjects with use of antibiotics [ Time Frame: Up to 12 months ]
    Number of subjects with use of antibiotics will be analyzed using data from subject files.

  12. Number of subjects receiving any COPD medication [ Time Frame: Up to 12 months ]
    Number of subjects receiving any COPD medication will be analyzed using data from subject files.

  13. Number of subjects with history of exacerbations [ Time Frame: Up to 12 months ]
    Number of subjects with history of exacerbations will be analyzed using data from subject files.

  14. Number of subjects with hospitalization for COPD [ Time Frame: Up to 12 months ]
    Number of subjects with hospitalization for COPD will be analyzed using data from subject files.

  15. Number of subjects with emergency room visits related to COPD [ Time Frame: Up to 12 months ]
    Number of subjects with emergency room visits related to COPD will be analyzed using data from subject files.

  16. Number of subjects with concomitant diseases [ Time Frame: Up to 12 months ]
    Number of subjects with concomitant diseases will be analyzed using data from subject files.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   35 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Sampling Method:   Probability Sample
Study Population
Approximately 30 lung specialists (up to 50) in Germany with sufficient number of COPD subjects under supervision in a hospital or office based setting will be enrolled in the study. Data from the survey of lung specialists and retrospective medical data of 250 subjects with COPD under supervision of the 30 lung specialists (up to 50) enrolled in the study will be included in the analysis.
Criteria

Inclusion Criteria:

For participating centers (Sample 1: 30 lung specialists from Germany)

  • More than 10 years of experience in respiratory medicine
  • At least 500 subjects under supervision in hospital- or office-based setting: a) Focus on obstructive lung diseases. b) Board certification. c) Informed consent to participate in this study and to share files of consenting subjects.

For subjects (Sample 2: 250 COPD subjects from these 30 doctors from sample 1)

  • Written informed consent to use his/her data.
  • Age >=40 years
  • Pack years >10, current or former smoking
  • Duration of COPD: >=1 year since COPD diagnosis record in subject files (also confirmed by spirometry)
  • No concurrent asthma diagnosis
  • At least one year of documented disease history at participating study doctors and have to be under the care of the before mentioned physician during this time because of COPD.

Exclusion Criteria:

  • Subjects who are pregnant and breastfeeding (in the last 12 months)
  • Subjects currently participating in any interventional study
  • Subjects with severe comorbidities which would have influence on the COPD therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03465332


Locations
Germany
GSK Investigational Site
Bruchsal, Baden-Wuerttemberg, Germany, 76646
GSK Investigational Site
Ulm, Baden-Wuerttemberg, Germany, 89073
GSK Investigational Site
Garmisch-Partenirchen, Bayern, Germany, 82467
GSK Investigational Site
Nuernberg, Bayern, Germany, 90489
GSK Investigational Site
Beelitz, Brandenburg, Germany, 14547
GSK Investigational Site
Cottbus, Brandenburg, Germany, 03050
GSK Investigational Site
Fuerstenwalde, Brandenburg, Germany, 15517
GSK Investigational Site
Kyritz, Brandenburg, Germany, 16866
GSK Investigational Site
Potsdam, Brandenburg, Germany, 14467
GSK Investigational Site
Frankfurt, Hessen, Germany, 60389
GSK Investigational Site
Wiesbaden, Hessen, Germany, 65183
GSK Investigational Site
Rostock, Mecklenburg-Vorpommern, Germany, 18107
GSK Investigational Site
Guetersloh, Nordrhein-Westfalen, Germany, 33330
GSK Investigational Site
Menden, Nordrhein-Westfalen, Germany, 58706
GSK Investigational Site
Warendorf, Nordrhein-Westfalen, Germany, 48231
GSK Investigational Site
Koblenz, Rheinland-Pfalz, Germany, 56068
GSK Investigational Site
Halberstadt, Sachsen-Anhalt, Germany, 38820
GSK Investigational Site
Halle, Sachsen-Anhalt, Germany, 06108
GSK Investigational Site
Hettstedt, Sachsen-Anhalt, Germany, 06333
GSK Investigational Site
Lutherstadt Wittenberg, Sachsen-Anhalt, Germany, 06886
GSK Investigational Site
Leipzig, Sachsen, Germany, 04103
GSK Investigational Site
Leipzig, Sachsen, Germany, 04157
GSK Investigational Site
Leipzig, Sachsen, Germany, 04357
GSK Investigational Site
Schleswig, Schleswig-Holstein, Germany, 24837
GSK Investigational Site
Berlin, Germany, 10625
GSK Investigational Site
Berlin, Germany, 13057
Sponsors and Collaborators
GlaxoSmithKline
Institut Dr. Schauerte (IDS)
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
Study Director: GSK Clinical Trials GlaxoSmithKline (for GlaxoSmithKline; Human Genome Sciences Inc., a GSK Company; Sirtris, a GSK Company; Stiefel, a GSK Company; ViiV Healthcare)

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT03465332     History of Changes
Other Study ID Numbers: 207733
First Posted: March 14, 2018    Key Record Dates
Last Update Posted: January 15, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by GlaxoSmithKline:
blood eosinophil count
COPD
diagnostic test
doctor's questionnaire
Lung specialist

Additional relevant MeSH terms:
Lung Diseases
Pulmonary Disease, Chronic Obstructive
Chronic Disease
Respiratory Tract Diseases
Lung Diseases, Obstructive
Disease Attributes
Pathologic Processes